Exposure to Phenols, Phthalates, and Parabens and Development of Metabolic Syndrome Among Mexican Women in Midlife
Open Access
- 26 February 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Public Health
Abstract
Background: Evidence suggests exposure to endocrine-disrupting chemicals (EDCs) can influence Metabolic Syndrome (MetS) risk in adults, but it is unclear if EDCs impact women during midlife. We examined if EDCs measured in adult women were predictive of MetS and its components 9 years later. Methods: We measured urinary phthalate metabolites, phenols, and parabens collected in 2008 among 73 females from the ELEMENT study. MetS and its components (Abdominal Obesity, Hypertriglyceridemia, Cholesterolemia, Hypertension, and Hyperglycemia) were assessed in 2017. We regressed log-transformed EDC concentrations on MetS and MetS components using logistic regression, adjusting for age and physical activity. Results: At follow-up, the mean (SD) age was 46.6 (6.3) years; the prevalence of MetS was 34.3%. Sum of dibutyl phthalate metabolites (ΣDBP), monobenzyl phthalate (MBzP), and monoethyl phthalate (MEP) were associated with an increased odds of hypertriglyceridemia. 2,5-dichlorophenol (2,5 DCP) and 2,4-dichlorophenol (2,4 DCP) were associated with increased odds of hypertriglyceridemia. The odds of hypertension were 4.18 (95% CI: 0.98, 17.7, p < 0.10) and 3.77 (95% CI: 0.76, 18.62, p < 0.10) times higher for every IQR increase in MCOP and propyl paraben, respectively. The odds of hyperglycemia were 0.46 (95% CI: 0.18, 1.17 p < 0.10) times lower for every IQR increase in the sum of di-2-ethylhexyl phthalate metabolites (ΣDEHP), and the odds of abdominal obesity were 0.70 (95% CI: 0.40, 1.21, p < 0.10) lower for every IQR increase in the concentration of triclosan. Conclusion: We found EDCs measured in 2008 were marginally predictive of hypertriglyceridemia and hypertension 9 years later. Results suggest that lower exposure to certain toxicants was related to lower markers of metabolic risk among midlife women.Funding Information
- National Institutes of Health (R24 R24-ES-028502, R24ES028502 Supplement, 3R01ES00782, P01ES022844, P30 DK089503, P30ES017885)
- U.S. Environmental Protection Agency (RD83543601)
This publication has 55 references indexed in Scilit:
- Obesity in midlife: lifestyle and dietary strategiesClimacteric, 2019
- Endocrine Disrupting Chemicals: An Occult Mediator of Metabolic DiseaseFrontiers in Endocrinology, 2019
- Metabolic syndrome during female midlife: what are the risks?Climacteric, 2019
- The Menopausal TransitionObstetrics and Gynecology Clinics of North America, 2017
- Abdominal obesity and white matter microstructure in midlifeHuman Brain Mapping, 2017
- Metabolic SyndromeJournal of Cardiovascular Pharmacology and Therapeutics, 2017
- Associations between actigraphy-assessed sleep, inflammatory markers, and insulin resistance in the Midlife Development in the United States (MIDUS) studySleep Medicine, 2016
- Endocrine-Disrupting Chemicals: An Endocrine Society Scientific StatementEndocrine Reviews, 2009
- The Metabolic SyndromeArchives of Internal Medicine, 2003
- Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham populationAmerican Heart Journal, 1986